Harrow, Inc. · NASDAQ:HROW
Harrow — Investor Presentation (March 2025)
13 slides from Harrow's investor presentation, March 2025
Slide 1: Investor Presentation | March 2025
Investor Presentation | March 2025
Slide 2: Safe Harbor
Safe Harbor This presentation contains “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptio
Slide 3: Harrow's Ophthalmic Pharmaceutical Brands
Harrow’s Ophthalmic Pharmaceutical Brands |3| Investor Presentation | March 2025
Slide 4: Summary Financial Performance
Summary Financial Performance Fourth-Quarter and Full-Year 2024 Highlights(1): • Revenues: $66.8 million for Q4 2024; $199.6 million for FY 2024 • Net Income (GAAP): $6.8 million for Q4 2024; GAAP net loss of $(17.5) million for FY 2024 • Core Net Income: $11.4 million for Q4 2024; core net loss of
Slide 5: Key Financial Metrics
Key Financial Metrics (in thousands) ‘25 Guidance $40,327 > $280,000 $28,119 $199,614 $130,193 $13,017 $88,595 $11,378 $72,476 $48,871 $5,715 20 21 22 23 24 25 20 21 22 23 24 Consolidated Revenues Adjusted EBITDA(1) (1) Adjusted EBITDA is defined as net income (loss), excluding the effects of stock-
Slide 6: IHEEZO
IHEEZO IHEEZO Quarterly Customer Unit Demand* (May 2023 launch) 49,130 34,468 30,016 15,176 Q1 2024 Q2 2024 Q3 2024 Q4 2024 *Customer Unit Demand reflects the number of units purchased by surgery centers, clinic/group practices, and physicians from Harrow’s distributors. This metric began in May 202
Slide 7: VEVYE
VEVYE VEVYE Quarterly Prescriptions (January 2024 launch) (Based on data from IQVIA) 63,925 44,513 28,796 6,522 Q1 2024 Q2 2024 Q3 2024 Q4 2024 |7| Investor Presentation | March 2025
Slide 8: TRIESENCE
TRIESENCE Description:(1) • The only FDA-approved preservative-free synthetic corticosteroid with separate reimbursement in all traditional settings of care • Indications: • Visualization During Vitrectomy (420,000 procedures per year) • Posterior Uveitis (100,000 diagnoses per year) Supply Chain: •
Slide 9: Anterior Segment Products
Anterior Segment Products Portfolio includes: • Steroids, NSAIDs, and Anti-inflammatories • An OTC preservative-free lubricant • An Antihistamine, and Antibiotics • The only FDA-approved Antifungal • Medication to treat vernal keratoconjunctivitis, a rare disease • Anti-glaucoma medications |9| Inve
Slide 10: ImprimisRx
ImprimisRx Revenues* (Dollars in thousands) $82,013 $83,499 $79,935 $69,104 $48,475 20 21 22 23 24 *Excludes revenue From DEXYCU® in all years; 2023 revenues reflect sale of Company’s non-ophthalmic business. ImprimisRx’s revenue is for compounded products, which are not FDA-approved | 10 | Investor
Slide 11: Equity Ownership – Melt Pharmaceuticals
Equity Ownership – Melt Pharmaceuticals Melt Pharmaceuticals is a former subsidiary of Harrow MELT-300 is a non-IV and non-opioid sublingual sedation drug candidate for short-duration medical procedures MELT-300 is patented in the U.S. and key global markets Harrow Others Potential impact in >100 mi
Slide 12: Commitment to Supporting Mission Trips
Commitment to Supporting Mission Trips See Intl Eye Doctors of Lancaster Nevis Eye Care Health in Sight Missions (Honduras) (Africa) (West Indies) (Honduras) April 2024 October 2024 November 2024 February 2025 During 2024, Harrow’s donations helped approximately To date, in 2025, Harrow has committe
Slide 13: 1A Burton Hills Blvd., Suite 200 Nashville, Tennessee 37215 www.Harrow.com
1A Burton Hills Blvd., Suite 200 Nashville, Tennessee 37215 www.Harrow.com Jamie Webb Director of Communications and Investor Relations jwebb@harrowinc.com Direct: 615-733-4737